insulin
- Generic Name
- insulin
SELESTIAL: Trial of Insulin to Control Blood Sugar After Acute Stroke Using Magnetic Resonance Imaging (MRI) End-Points
- Conditions
- Acute StrokeHyperglycemia
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2006-02-01
- Lead Sponsor
- University of Glasgow
- Target Recruit Count
- 45
- Registration Number
- NCT00124826
- Locations
- π¬π§
Institute of Neurological Sciences, Glasgow, United Kingdom
Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110864
- Locations
- πΊπΈ
Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
πΊπΈBaptist Diabetes Associates, Miami, Florida, United States
πΊπΈCOR Clinical Research, LLC, Oklahoma City, Oklahoma, United States
Glucontrol Study: Comparing the Effects of Two Glucose Control Regimens by Insulin in Intensive Care Unit Patients
- Conditions
- Critical Illness
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2008-06-27
- Lead Sponsor
- University of Liege
- Target Recruit Count
- 3500
- Registration Number
- NCT00107601
- Locations
- π³π±
V.U.Z. Amsterdam, Amsterdam, Netherlands
π¨πC.H.U. Vaudois, Lausanne, Switzerland
πͺπΈHospital Universitario General Negrin, Las Palmas de Gran Canaria, Spain
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
- First Posted Date
- 2004-12-13
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00099333
- Locations
- πΊπΈ
Research Site, San Antonio, Texas, United States
Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: human insulin inhalation powder (HIIP)
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 119
- Registration Number
- NCT00063128
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, West Virginia, United States
Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation
- Conditions
- Hyperinsulinemia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 16
- Registration Number
- NCT00001624
- Locations
- πΊπΈ
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2002-03-22
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 1791
- Registration Number
- NCT00032487
- Locations
- πΊπΈ
Southern Arizona VA Health Care System, Tucson, Tucson, Arizona, United States
πΊπΈVA Medical Center, Long Beach, Long Beach, California, United States
πΊπΈEdward Hines, Jr. VA Hospital, Hines, Illinois, United States
Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2001-04-11
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 36
- Registration Number
- NCT00014768
- Locations
- πΊπΈ
University of Utah School of Medicine, Salt Lake City, Utah, United States
Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
- Conditions
- Infant, Low Birth WeightHyperglycemia
- First Posted Date
- 2000-06-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 96
- Registration Number
- NCT00005889
- Locations
- πΊπΈ
Baylor College of Medicine, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.